Baltic Amber Gives Rise to Paleopharmaceuticals

Each year in the U.S., at least 2.8 million people get antibiotic-resistant infections, leading to 35,000 deaths, according to the U.S. CDC. Ancient amber (fossilized tree resin) have been used by humans in Baltic countries for medicinal purposes for centuries. Now, researchers from the University of Minnesota have pinpointed compounds that help explain Baltic amber's therapeutic effects and that could lead to new medicines to combat antibiotic-resistant infections.

CARB-X Funds Optimization, Scaleup, and Production of New Gonorrhea Vaccine

The vaccine aims to curb the global spread of gonorrhea and strains of super gonorrhea antibiotic-resistant bacteria.

CRISPR Single-Cell Screening Drives Biological Discovery

In this GEN webinar, sponsored by Horizon Discovery, we will present data showing how a new CRISPRsc screening platform from Horizon offers a streamlined approach to elucidating valuable and intriguing biological information critical to resolving complex biological questions.

Sanofi Inks Agreement to Build Influenza Vaccine Manufacturing Facility in Canada

Canadian officials say the investment demonstrates the government’s commitment to grow domestic manufacturing capacity and to prepare for future pandemics.

Epizyme Charts Five-Year Clinical Vision, Seeing Silver Linings Amid Tazverik Clouds

Epizyme recently detailed its development strategy and pipeline priorities over the next five years during a “Strategic Vision Call.” Those priorities include launching two signal-finding “basket” studies in the second half of 2021 to evaluate tazemetostat safety and efficacy across multiple new types of blood and solid tumors; and advancing to the clinic its SETD2 inhibitor program.

Funding the Next Generation of Cancer Therapies

Investors are favoring biopharmaceutical firms that plan to launch orchestrated attacks on cancer—attacks that engage multiple immune mechanisms to overcome resistance.

AI in Drug Discovery Starts to Live Up to the Hype

The past few years have seen several flashy demonstrations of how artificial intelligence (AI) algorithms may transform biomedical research, particularly with respect to drug discovery. AI’s champions in the industry remain wary about overselling the technology’s current capabilities. Nevertheless, a growing number of companies now recognize the value that AI—and more specifically, the subset of algorithmic techniques known as “machine learning”—can deliver at various stages in the drug discovery process.

Gene Therapies Receive a Shot in the Arm

Developers of gene therapies are taking advantage of new vector technologies, incorporating CRISPR systems, and augmenting gene therapy with targeted therapies and immunotherapies.

BridgeBio, Helsinn Ink Up-to-$2.4B Infigratinib Partnership

The collaboration comes as the FDA is reviewing an NDA for infigratinib in patients with previously treated, FGFR-mutant cholangiocarcinoma (bile duct cancer).

Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B

Scribe—one of a new wave of gene editing biotech companies—focuses on developing CRISPR-based treatments through its genetic modification platform, designed to build and apply its suite of CRISPR technologies designed for therapeutic use.

Recently Featured

Scroll Up